ES2170286T3 - Derivados de pirido(2,3-b)pirazina. - Google Patents

Derivados de pirido(2,3-b)pirazina.

Info

Publication number
ES2170286T3
ES2170286T3 ES96941882T ES96941882T ES2170286T3 ES 2170286 T3 ES2170286 T3 ES 2170286T3 ES 96941882 T ES96941882 T ES 96941882T ES 96941882 T ES96941882 T ES 96941882T ES 2170286 T3 ES2170286 T3 ES 2170286T3
Authority
ES
Spain
Prior art keywords
phenyll
rent
amino
alquenilo
piridil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96941882T
Other languages
English (en)
Inventor
Norihiko Shimazaki
Akihiko Sawada
Shinya Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2170286T3 publication Critical patent/ES2170286T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

COMPUESTOS DE FORMULA (I), EN DONDE R 1 ES PIRIDIL ALQUIL(INFERIOR), N - OXIDOPIRIDIL - ALQUIL(INFERIOR) O IMIDAZOLIL - ALQUIL(INFERIOR); R 2 ES AMINOFENIL, [PROTEGIDO AMI NO]FENILO, [[[HALOFENIL]ALQUENOIL(INFERIOR)]AMINO]FENILO, [[PIRIDIL - ALQUENOIL(INFERIOR)]AMINO]FENILO, [[[N OXIDOPIRIDIL]ALQUENOIL(INFERIOR)] - AMINO]FENILO,[[[AMINOPIRIDIL PROTEGIDO]ALQUENOIL(INFERIOR)]AMINO] - FENILO, [TIAZOLILCARBONILAMINO]FENILO QUE PUEDE SER PIRIDILO, NAFTILO CON ALCOXI INFERIOR Y HALOGENO, [DIHALOFENIL]ALQUENILO(INFERIOR), [N - OXIDOPIRIDIL]ALQUENILO(INFERIOR), [AMINOPIRIDIL]ALQUENILO(INFERIOR), [AMINOPIRIDIL PROTEGIDO]ALQUENILO(INFERIOR), [CARBOXIPIRIDIL]ALQUENILO(INFERIOR), [CARBOXIPIRIDIL PROTEGIDO]ALQUENILO(INFERIOR), [[PIRIDIL ALQUENILO(INFERIOR)]PIRIDIL]ALQUENILO(INFERIOR), [[CARBOXI ALQUENIL(INFERIOR)]PIRIDIL]ALQUENILO(INFERIOR), [[CARBOXI PROTEGIDO - ALQUENIL(INFERIOR)]PIRIDIL]ALQUENILO(INFERIOR), [PIRIDIL - ALQUENIL(INFERIOR)]PIRIDILO, ALQUIL - BENZOTIAZOLIL (LE ALQUILO INFERIOR) O [HALOPIRIDILCARBONIL]AMINO, CON LA CONDICION DE QUE SI R 2 ES [[4 - PIRIDILALQUENOIL(INFERIOR)]AMINO]FENILO, AMINOFENILO, [ALCANOILAMINO INFERIOR]FENILO O [DIHALOFENIL]ALQUENILO(INFERIOR), ENTONCES R 1 ES N - OXIDOPIRIDIL - ALQUILO(INFERIOR) O IMIDAZOLIL ALQUILO(INFERIOR); TIENE UNA FUERTE ACTIVIDAD INHIBITORIA DE LA FOSFODIESTERASA IV (PDE IV) Y UNA FUERTE ACTIVIDAD INHIBITORIA SOBRE LA PRODUCCION DEL FACTOR DE NECROSIS TUMORAL (TNF).
ES96941882T 1995-12-27 1996-12-13 Derivados de pirido(2,3-b)pirazina. Expired - Lifetime ES2170286T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9526558.3A GB9526558D0 (en) 1995-12-27 1995-12-27 Heterobicyclic derivatives

Publications (1)

Publication Number Publication Date
ES2170286T3 true ES2170286T3 (es) 2002-08-01

Family

ID=10786098

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96941882T Expired - Lifetime ES2170286T3 (es) 1995-12-27 1996-12-13 Derivados de pirido(2,3-b)pirazina.

Country Status (18)

Country Link
US (1) US6117875A (es)
EP (1) EP0874845B1 (es)
JP (1) JP2000502699A (es)
KR (1) KR19990072053A (es)
CN (1) CN1066732C (es)
AT (1) ATE214067T1 (es)
AU (1) AU720301B2 (es)
CA (1) CA2241690A1 (es)
DE (1) DE69619702T2 (es)
DK (1) DK0874845T3 (es)
EA (1) EA001324B1 (es)
ES (1) ES2170286T3 (es)
GB (1) GB9526558D0 (es)
HU (1) HUP9901038A3 (es)
IL (1) IL124673A (es)
MX (1) MX9805129A (es)
PT (1) PT874845E (es)
WO (1) WO1997024355A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
PT1212089E (pt) 1999-08-21 2006-08-31 Altana Pharma Ag Combinacao sinergica de roflumilast e salmeterol
NZ519981A (en) 2000-01-20 2005-02-25 Eisai Co Ltd Nitrogenous cyclic compounds and pharmaceutical compositions containing the same
CN1307159C (zh) 2000-05-31 2007-03-28 参天制药株式会社 TNF－α生成抑制剂
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
CN100572381C (zh) * 2002-11-06 2009-12-23 Aska制药株式会社 吡唑并二氮杂萘衍生物
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
EP1729771B1 (en) 2004-03-22 2009-10-14 Eli Lilly & Company Pyridyl derivatives and their use as mglu5 receptor antagonists
CA2603830A1 (en) * 2005-05-24 2006-11-30 Pharmacia & Upjohn Co Llc PYRIDINE [2,3-B] PYRAZINONES
US20080280891A1 (en) * 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
MX2010009577A (es) * 2008-03-05 2010-09-24 Merck Patent Gmbh Derivados de piridopirazinona que estimulan la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes.
WO2010096426A2 (en) * 2009-02-20 2010-08-26 Emory University Compounds, compositions, methods of synthesis, and methods of treatment
CN101875627B (zh) * 2009-04-30 2014-01-15 凯惠科技发展(上海)有限公司 一种1-烷氧羰基-2h-异吲哚衍生物及其制备方法和中间体
JP2022532178A (ja) * 2019-05-10 2022-07-13 上海海雁医薬科技有限公司 置換フェニルプロペニルピリジン誘導体、その調製方法及びその医学的使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008864A1 (en) * 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
GB9413975D0 (en) * 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives

Also Published As

Publication number Publication date
IL124673A (en) 2002-07-25
CN1205702A (zh) 1999-01-20
WO1997024355A1 (en) 1997-07-10
JP2000502699A (ja) 2000-03-07
EP0874845A1 (en) 1998-11-04
CA2241690A1 (en) 1997-07-10
DE69619702D1 (de) 2002-04-11
DE69619702T2 (de) 2002-08-14
KR19990072053A (ko) 1999-09-27
GB9526558D0 (en) 1996-02-28
HUP9901038A3 (en) 2000-04-28
EP0874845B1 (en) 2002-03-06
EA199800599A1 (ru) 1998-12-24
DK0874845T3 (da) 2002-07-01
MX9805129A (es) 1998-10-31
AU1111297A (en) 1997-07-28
HUP9901038A2 (hu) 1999-07-28
US6117875A (en) 2000-09-12
CN1066732C (zh) 2001-06-06
PT874845E (pt) 2002-08-30
IL124673A0 (en) 1998-12-06
EA001324B1 (ru) 2001-02-26
AU720301B2 (en) 2000-05-25
ATE214067T1 (de) 2002-03-15

Similar Documents

Publication Publication Date Title
ES2170286T3 (es) Derivados de pirido(2,3-b)pirazina.
ES2189968T3 (es) Amidinofenil-pirrolidinas,-pirrolinas,e -isoxazolidinas y derivadOS DE LOS MISMOS.
TR199700844T1 (xx) Pirazolil-Benzoil T�revleri.
GR3036887T3 (en) Meta-substituted phenylene sulphonamide derivatives
AP2002002637A0 (en) Novel piperazine
CA2078790A1 (en) 3-benzylidene-1-carbamoyl-2-pyrrolidone analogues
ATE194335T1 (de) 4,5-diaryloxazol-derivate
WO1998028282A3 (en) OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
MA26812A1 (fr) Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases
NO975245D0 (no) Heterocykluser som inhibitorer av laukocyttadhesjon og VLA-4-antagonister
CA2340999A1 (en) 5-arylindole derivatives
ATE217006T1 (de) Tetrahydronaphthalin-derivate und ihre therapeutische verwendung
ATE231149T1 (de) (1,8)-naphthyridinderivate derivate mit antiviraler wirkung
BR0014651A (pt) Inibidores de adesão de célula mediada por "alfa" l beta2
FI963169A0 (fi) Enkefalinaasin ja ACE:n inhibittoreina käyttökelpoisia uusia merkaptoasetyyliamido-1,3,4,5-tetrahydrobents/c/-atsepin-3-onidisulfidijohdannaisia
YU21100A (sh) Izohinolini kao urokinazni inhibitori
ATE251153T1 (de) Neue thiazol-derivate mit phosphodiesterase inhibierender wirkung
DE3585980D1 (de) Hydrazinderivate und ihre verwendung.
CA2134077A1 (en) 4-imidomethyl-1-[2'phenyl-2'oxoethyl-]piperidines as serotonin 5ht2-antagonists, their preparation and use in therapy
AU5727899A (en) Diaminocyclobutene-3,4-dione derivatives, their preparation and use
TR200000697T2 (tr) İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin-10-OL'ler, üretim yöntemleri ve farmasötik preparat olarak kullanımları.
ATE162931T1 (de) Menschlicher elastase-inhibitor
CO5040091A1 (es) Derivados de urea
BG106922A (en) Heterocyclic amide derivatives

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 874845

Country of ref document: ES